Ocul Immunol Inflamm
a Laboratory of Cellular and Molecular Immunology , Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine , California , USA .
Published: June 2016
Dry eye disease (DED) is a prevalent public health concern that affects up to 30% of adults and is particularly chronic and severe in the elderly. Two interconnected mechanisms cause DED: (1) an age-related dysfunction of lacrimal and meibomian glands, which leads to decreased tear production and/or an increase in tear evaporation; and (2) an age-related uncontrolled inflammation of the surface of the eye triggered by yet-to-be-determined internal immunopathological mechanisms, independent of tear deficiency and evaporation. In this review we summarize current knowledge on animal models that mimic both the severity and chronicity of inflammatory DED and that have been reliably used to provide insights into the immunopathological mechanisms of DED, and we provide an overview of the opportunities and limitations of the rabbit model in investigating the role of both ocular and nasal mucosal immune systems in the immunopathology of inflammatory DED and in testing novel immunotherapies aimed at delaying or reversing the uncontrolled age-related inflammatory DED.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478284 | PMC |
http://dx.doi.org/10.3109/09273948.2014.986581 | DOI Listing |
Orbit
March 2025
Brien Holden Eye Research Center (BHERC), LV Prasad Eye Institute, Hyderabad, India.
Parkinson's disease is characterized by motor dysfunction, affecting blink frequency in the eyes. Reduced blinking and use of anticholinergic medications result in dry eye disease (DED) in these patients. This unique case had complete meibomian gland loss seen on meibography with reduced blinking and lacrimal gland function as well attributed to Parkinson's and its treatment.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Institute of Functional and Clinical Anatomy, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Dry eye disease (DED) is often seen in patients with polyneuropathies (PNs), but the relationship between the different forms of PNs and DED is not known. In oxaliplatin (Ox-)-treated mice with PNs, morphological changes in the sciatic nerve (SN), dorsal root ganglia (DRG), trigeminal ganglia (TG), and the ocular tissues involved in tear formation were investigated. In addition, the tear proteomics and the gene expression of related proteins in the ocular surface tissues as well as inflammatory factors were analyzed.
View Article and Find Full Text PDFInt J Pharm
March 2025
School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India. Electronic address:
In this study, quercetin-incorporated squalene nanostructured lipid carriers (QS-NLCs) were developed to mitigate the pathological conditions of dry eye disease (DED). The melt emulsification method was used to prepare QS-NLCs. The resulting NLCs have 93.
View Article and Find Full Text PDFExp Eye Res
March 2025
Department of Ophthalmology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing, China. Electronic address:
Dry eye disease (DED) is a complex ocular condition characterized by oxidative stress, inflammation, and apoptosis. An increasing number of studies suggest that Sirtuin3 (SIRT3), a mitochondrial deacetylase, may offer protection against related pathologies. Despite these indications, the precise function and underlying mechanisms of SIRT3 in the context of DED have not been fully elucidated.
View Article and Find Full Text PDFThis report explores the management of an otherwise healthy 31-year-old Caucasian female with chronic, refractory dry eye disease (DED) unresponsive to extensive conventional therapies. The initial treatment included artificial tears, cyclosporine, hypochlorous acid spray, and thermal eyelid pulsation, which provided limited relief. Progressive therapeutic interventions, such as intense pulsed light, varenicline nasal spray, perfluorohexyloctane drops, platelet-rich plasma, and topical antibiotics, resulted in only modest improvement over 15 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.